Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems for the manufacturing of biological drugs. The company operates as a single bioprocessing business with four main franchises: Filtration, Chromatography, Process Analytics, and Proteins. Its product portfolio includes upstream and downstream solutions such as XCell ATF cell retention systems, TangenX flat sheet cassettes, KrosFlo tangential flow filtration systems, OPUS pre-packed columns, and PATsmart process analytics tools. Repligen also offers fluid management components and dialysis products under the SpectraPor and ProConnex brands. The company serves global biopharmaceutical companies, contract development and manufacturing organizations, and other life science integrators. It markets its products globally through a direct commercial organization in the United States, Europe, and Asia, as well as through strategic partners and distributors. Founded in 1981, Repligen has expanded its portfolio through internal research and development and strategic acquisitions, including BioLife Solutions and Metenova.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage repligen.com
Sector Healthcare IR page investors.repligen.com/overview/default.aspx
Tags
bioprocessing, filtration, chromatography, process analytics, single-use technologies, tangential flow filtration, cell culture, biologics manufacturing, viral vector manufacturing, dialysis, XCell ATF, TangenX, SIUS, KrosFlo, OPUS, PATsmart, SpectraPor, ProConnex, BioLife Solutions, Metenova, AVIPure, CaptivA, SpectraFlo, Float-A-Lyzer, Tube-A-Lyzer, REBEL XT, MAVEN, ZipChip, SoloVPE PLUS, MixOne RG-X
Press page —

Metrics

Valuation  
Market cap $ 10.453B
Market cap (USD) $ 10.453B
P/E -921.88
PEG —
P/BV 5.00
P/S 12.97
P/OCF 80.49
P/FCF 97.95
Dividend yield —
Turnover / mcap —
Returns  
ROE 2.4%
ROI 1.8%
ROIC 1.6%
Profit margin 6.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -35.9%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 26.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 64
Quality score -16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Revenue 738.256M 634.439M 638.764M 801.536M 670.534M 366.26M 270.245M 194.032M 141.236M 104.541M 83.537M 63.548M 68.17M 62.267M — 29.362M 19.296M 14.074M 12.911M 9.36M 6.914M 7.772M 4.302M 2.347M 3.525M 2.59M
Net profit 48.894M -25.514M 41.577M 185.959M 128.291M 59.926M 21.411M 16.617M 28.353M 11.681M 9.345M 8.17M 16.093M 14.156M — 5.746M 37.107M -889.263K 696.86K -2.984M -9.551M -4.537M -4.461M -5.279M -3.816M -2.544M
Free cash flow 93.898M 149.717M 77.696M 87.249M 51.927M 40.17M 48.712M 22.135M 11.997M 3.196M 12.425M 12.799M 21.295M 12.176M — 4.967M 37.364M -921.047K -320.111K -847.935K -6.026M -6.341M -5.062M -4.805M -3.352M -1.475M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Share price 163.86 143.94 179.8 169.31 264.84 191.63 92.5 52.74 36.28 30.82 28.29 19.8 13.64 6.3 3.49 3.5 5.38 3.15 4.5 1.72 4.96 — — — — —
Price performance 12m 0.14 -0.2 0.06 -0.36 0.38 1.07 0.75 0.45 0.18 0.09 0.43 0.45 1.16 0.81 — -0.35 0.71 -0.3 1.62 -0.65 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 15.2M 27.6M 33M 43.1M 71.3M 117M 116M 124M 134M 159M
↳ YoY growth +34.5% +81.6% +19.7% +30.4% +65.6% +64.7% -1.0% +6.8% +8.0% +18.2%
↳ 5y CAGR +40.0% +46.0% +46.2% +40.9% +44.5% +50.5% +33.3% +30.3% +25.5% +17.3%
Lease liabilities (USD) — — — 30.6M 31.7M 111M 138M 132M 161M 148M
Cash and deposits (USD) 122M 174M 194M 528M 717M 604M 523M 751M 757M 566M
Intangible assets (USD) 29.8M 145M 135M 213M 287M 337M 354M 400M 398M 386M
Right-of-use assets (USD) — — — 25.7M 25.2M 102M 125M 116M 135M 120M
Cash flow detail
Operating cash flow (USD) 7.52M 17.5M 32.8M 67.2M 62.6M 119M 172M 114M 175M 117M
Purchases of property, plant and equipment (USD) -4.33M -5.45M -10.6M -18.5M -22.5M -67.1M -84.8M -36.2M -25.7M -23.5M
Purchases of intangible assets (USD) — — — — 0.00 0.00 -45M 0.00 -3.01M 0.00
Change in receivables (cash effect) (USD) -3.22M -6.89M -6.1M -7.73M -21M -46.5M -3.6M -3.31M -14M -17.2M
Change in inventories (cash effect) (USD) -6.16M 605,000 -4.04M -9.31M -29.3M -89.8M -57.2M 41M 56.9M -14.9M
Change in payables (cash effect) (USD) -1.8M 807,000 2.27M 662,000 2.46M 19.5M -8.2M -9.8M 12.9M -4.15M
Share buybacks (cash effect) (USD) — — — — — 0.00 0.00 -14.4M 0.00 0.00
Interest paid (cash effect) (USD) -1.22M -2.44M -2.44M -1.48M -1.07M -1.07M -1.03M -988,000 -6.07M —
Income taxes paid (cash effect) (USD) -3.99M -4.02M -4.05M -6.51M -10.3M -16.5M -34.4M -27M -19.3M -20.9M
Share-based compensation (USD) 4.6M 6.75M 10.2M 12.8M 17M 27.5M 27.3M 25.6M 48.1M 32.6M
Operating cash flow before change in receivables (USD) 10.7M 24.3M 38.9M 74.9M 83.6M 166M 176M 117M 189M 135M
Free cash flow (OCF - PPE - intangibles) (USD) 3.2M 12M 22.1M 48.7M 40.2M 51.9M 42.2M 77.7M 147M 93.9M
Income detail
Research and development expense (USD) 7.36M 8.67M 15.8M 19.5M 20.2M 34.3M 43.9M 42.7M 43.2M 54.2M
↳ 5y CAGR -3.7% +16.6% +28.2% +28.6% +36.0% +38.3% +22.0% +17.3% +21.8%
Total comprehensive income (USD) 6.5M 35.7M 11.1M 18.3M 77M 109M 168M 38.5M -40.2M 98.9M
Comprehensive income to owners (USD) 6.5M 35.7M 11.1M 18.3M 77M 109M 168M 38.5M -40.2M 98.9M
Provision for credit losses (USD) — — — — -339,000 -828,000 -74,000 -839,000 155,000 —
Credit cost ratio (credit losses / average receivables) (%) — — — — 0.6% 0.9% 0.1% 0.7% 0.1% —
Reported Feb 22, 2018 Feb 22, 2018 Mar 1, 2019 Feb 26, 2020 Feb 22, 2023 Feb 22, 2024 Feb 22, 2024 Feb 22, 2024 Mar 14, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 6, 2026, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the “Company”) issued $1.0 billion aggregate principal amount of its 0.25% Convertible Senior Notes due 2031 (the “New Notes”) under an Indenture, dated November 6, 2026 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee. Approximately $541.4 million principal amount of the New Notes was issued in exchange for approximately $456.8 million principal amount of the Company’s 1.00% Convertible Senior Notes due 2028 (the “2028 Notes”) (the “Exchange Transactions”), which 2028 Notes were promptly canceled upon exchange, and approximately $458.6 million principal amount of the New Notes was issued for approximately $458.6 million in cash (the “Subscription Transactions” and, together with the Exchange Transactions, the “Transactions”). Following the closing of the Transactions, approximately $143.2 million in aggregate principal amount of 2028 Notes remains outstanding with terms unchanged.

Nov 4, 2026

WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst-led discussion on November 18th at 2:00 p.m. GMT.

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website and will be available for replay for a limited period of time following the event.

About Repligen Corporation
Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies and integrated solutions that support critical steps in the manufacturing and delivery of biologic drugs that improve human health worldwide. As a trusted partner to biopharmaceutical developers and manufacturers and CDMOs worldwide, we help improve productivity, simplify complex workflows, and advance the next generation of biologic therapies. Repligen technologies support the production of a broad range of biologic modalities, helping customers navigate evolving manufacturing challenges from process development through commercial production. Our global team combines deep scientific expertise, innovation, and a customer-focused mindset “inspiring advances in bioprocessing” to help solve complex challenges across biologics manufacturing. For more information, please visit our website at www.repligen.com , and follow us on LinkedIn .

Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
[email protected]

Primary Logo

Source: Repligen Corporation

View All News

repligen logo

Personal Information

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

  • Press Releases
  • Quarterly Reports
  • Annual Reports
  • SEC Filings
  • End of Day Stock Quote
  • Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again. Sign Up

© 2026 Repligen Corporation. All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Oct 30, 2026

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 1.00% Convertible Senior Notes due 2028 (the “2028 Notes”) and certain new investors, pursuant to which Repligen will issue $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031 (the “New Notes”). Approximately $541.4 million principal amount of the New Notes will be issued in exchange for approximately $456.8 million principal amount of 2028 Notes (the “Exchange Transactions”) and approximately $458.6 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $226.37 per share of Repligen’s common stock, which represents a conversion premium of approximately 20% over the closing price of Repligen’s common stock on October 29, 2026, subject to customary anti-dilution adjustments. Following the closing of the Transactions, which is expected to occur on or about November 6, 2026, subject to customary closing conditions, approximately $143.2 million in aggregate principal amount of 2028 Notes will remain outstanding with terms unchanged.

Repligen estimates that the gross proceeds from the Subscription Transactions will be approximately $458.6 million, excluding fees payable to the placement agent for the Transactions and other offering expenses payable by Repligen. Repligen intends to use approximately $120.0 million of the net proceeds from the Subscription Transactions to repurchase shares of its common stock from certain purchasers of the New Notes through a financial intermediary at a price per share of $188.64, which is equal to the last reported sale price of its common stock on October 29, 2026, in order to facilitate the Transactions. Repligen intends to use the remainder of the net proceeds for working capital and general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies. Repligen will not receive any cash proceeds from the Exchange Transactions.

Jason Garland, Chief Financial Officer of Repligen, commented, “These transactions proactively address the upcoming maturity of our 2028 Notes, extend our debt duration, reduce our interest expense, and enhance our financial flexibility. The reduced interest expense is expected to be nominally accretive to adjusted EPS in 2026, with additional benefit expected in 2027. By strengthening our capital structure, we have increased our capacity to support both organic investments and disciplined M&A activity to drive long-term value creation for shareholders. In the near-term, we are focused on the successful integration of BioLife, and we remain excited about our expanded capabilities to serve the cell therapy end-market.”

In connection with the issuance of the New Notes, Repligen has been advised that the placement agent for the Transactions intends to purchase approximately $30.0 million of Repligen’s common stock from certain participants in the Transactions through a financial intermediary at a discount to the last reported sale price of the common stock on October 29, 2026.

Such concurrent repurchases by Repligen and purchases by the placement agent of Repligen’s common stock could increase (or reduce the size of any decrease in) the market price of Repligen’s common stock or the New Notes.

Additional information regarding this announcement may be found in a Current Report on Form 8-K that Repligen intends to file today with the U.S. Securities and Exchange Commission (the “SEC”).

J. Wood Capital Advisors LLC acted as placement agent to Repligen in connection with the Transactions.

This press release does not constitute an offer to sell, nor is it a solicitation of an offer to buy, the New Notes or Repligen’s common stock, nor shall there be any sale of the New Notes or Repligen’s common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or any jurisdiction.

About Repligen C****orporation

Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies and integrated solutions that support critical steps in the manufacturing and delivery of biologic drugs that improve human health worldwide. As a trusted partner to biopharmaceutical developers and manufacturers and CDMOs worldwide, we help improve productivity, simplify complex workflows, and advance the next generation of biologic therapies. Repligen technologies support the production of a broad range of biologic modalities, helping customers navigate evolving manufacturing challenges from process development through commercial production. Our global team combines deep scientific expertise, innovation, and a customer-focused mindset “inspiring advances in bioprocessing” to help solve complex challenges across biologics manufacturing. For more information, please visit our website at www.repligen.com , and follow us on LinkedIn .

Forward-Looking Statements

This press release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein which do not describe historical facts, including, among others, any express or implied statements or guidance regarding the closing of the Transactions, the purchase of Repligen’s common stock by Repligen and/or the placement agent for the Transactions, Repligen’s expectations regarding the expected net proceeds from the Subscription Transactions and the use of such proceeds and current or future financial performance and position, including our 2026 financial guidance and related assumptions; expected demand in the markets in which we operate; and the expected performance of our business and momentum across our portfolio, are based on management’s current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Such risks and uncertainties include, among others, our ability to successfully grow our bioprocessing business; our ability to manage through and predict headwinds; the risk that we have assumed that markets and franchises will improve and grow as predicted; our ability to achieve our 2026 financial guidance; our ability to develop and commercialize products and the market acceptance of our products; our ability to successfully integrate BioLife, including its operations, products, systems and personnel, in a timely manner or at all, and to realize the expected benefits and synergies of the acquisition; the future performance of BioLife and the combined company, including the impact of the acquisition on our financial results and outlook; the risk of unanticipated costs, liabilities or disruptions to our or BioLife's business, customer, supplier or employee relationships resulting from the acquisition; our ability to successfully integrate any other acquired businesses and relevant personnel in a timely manner or at all, and to achieve the expected benefits of such acquisitions; the risk that demand for our products could decline, which could adversely impact our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing companies; risks around the Company’s effectiveness of disclosure controls and procedures and the effectiveness of our internal control over financial reporting; our compliance with all U.S. Food and Drug Administration and European Medicines Evaluation Agency regulations; our volatile stock price; the impact of tariffs on our business, and other risks and uncertainties detailed in Repligen’s filings with the U.S. Securities and Exchange Commission (the Commission), including our Annual Report on Form 10-K for the year ended December 31, 2025 and in subsequently filed reports with the Commission, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any subsequent filings made with the Commission, which are available at the Commission’s website at www.sec.gov. Actual results may differ materially from those Repligen contemplated by these forward-looking statements, which reflect management’s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Repligen disclaims any obligation to update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

**Repligen Contact:
**Jacob Johnson
VP, Investor Relations
(781) 419-0204
[email protected]

Primary Logo

Source: Repligen Corporation

View All News

repligen logo

Personal Information

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

  • Press Releases
  • Quarterly Reports
  • Annual Reports
  • SEC Filings
  • End of Day Stock Quote
  • Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again. Sign Up

© 2026 Repligen Corporation. All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Prompts

Repligen Corporation (ticker RGEN), listed in United States.

Company History

Date Change Detail
Aug 6, 2026 Acquired Acquired Biolife Solutions Inc (CIK 834365). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Repligen Corporation

ETF Weight in ETF Shares Market value As of
FRTY 2.94% 33,150 $ 4.523M Jun 30, 2026
CSMD 2.78% 89,612 $ 12.636M Jul 31, 2026
BCSM 1.92% 4,671 $ 637.311K Jun 30, 2026
EVNT short -1.68% -1,216 $ -220.072K Aug 31, 2026
GDOC 1.65% 1,789 $ 323.773K Aug 31, 2026
FMED 1.47% 4,200 $ 760.116K Aug 31, 2026
MMSC 1.05% 3,221 $ 524.314K Nov 16, 2026
HELX 0.98% 2,009 $ 274.108K Jun 30, 2026
GSC 0.88% 13,623 $ 2.465M Aug 31, 2026
TMED 0.85% 1,430 $ 195.109K Jun 30, 2026
SSMG 0.71% 160 $ 22.562K Jul 31, 2026
FWD 0.50% 87,622 $ 15.858M Aug 31, 2026
BTAL short -0.44% -9,108 $ -1.243M Jun 30, 2026
SEIS 0.36% 15,207 $ 2.075M Jun 30, 2026
DFAS 0.22% 439,753 $ 73.228M Nov 12, 2026
TMSL 0.20% 40,414 $ 5.514M Jun 30, 2026
MKTN short -0.19% -1,476 $ -201.385K Jun 30, 2026
SPIN 0.19% 506 $ 82.367K Nov 16, 2026
FFSM 0.17% 17,851 $ 2.517M Jul 31, 2026
RILA 0.07% 213 $ 30.035K Jul 31, 2026
JMEE 0.07% 11,931 $ 1.935M Nov 17, 2026
MSSM 0.07% 2,568 $ 464.757K Aug 31, 2026
DFAC 0.04% 222,075 $ 36.98M Nov 12, 2026
DFSU 0.04% 5,328 $ 887.219K Nov 12, 2026
DCOR 0.02% 56,257 $ 9.368M Nov 12, 2026
AVLC 0.02% 1,725 $ 280.796K Nov 16, 2026
SMDX 0.02% 152 $ 24.743K Nov 17, 2026
DFAU 0.02% 13,267 $ 2.209M Nov 12, 2026
DFUS 0.01% 18,176 $ 3.027M Nov 12, 2026
DXUV 0.01% 3,791 $ 631.277K Nov 12, 2026
AVUS 0.01% 5,589 $ 909.777K Nov 16, 2026
AVSU 0.01% 173 $ 28.161K Nov 16, 2026
MSLC 0.01% 2,094 $ 378.972K Aug 31, 2026
EBI 0.00% 81 $ 14.659K Aug 31, 2026
DFUV 0.00% 461 $ 76.766K Nov 12, 2026
IALT 0.00% 74 $ 12.046K Nov 16, 2026
AVMC 0.00% 118 $ 19.208K Nov 16, 2026